Breaking News Instant updates and real-time market news.

GDOT

Green Dot

$59.60

0.7 (1.19%)

, AAPL

Apple

$187.07

-4.04 (-2.11%)

15:21
03/25/19
03/25
15:21
03/25/19
15:21

Apple Card could be $100M revenue opportunity for Green Dot, says Craig-Hallum

After Apple (AAPL) announced a new credit card earlier today, Craig-Hallum analyst Brad Berning noted that Green Dot (GDOT) powers Apple Pay Cash. If adoption rates for Apple Card follow Apple Pay's path, Apple Card could equate to a $100M potential annual gross revenue opportunity for Green Dot, Berning tells investors. The Apple Card news will not eliminate the market's concerns over the Walmart (WMT) renewal, but his view is that there will be numerous potential partnership opportunities for Green Dot to win over time, added Berning. He keeps a Buy rating on Green Dot shares with a $115 price target.

GDOT

Green Dot

$59.60

0.7 (1.19%)

AAPL

Apple

$187.07

-4.04 (-2.11%)

WMT

Walmart

$98.34

0.06 (0.06%)

  • 25

    Mar

  • 29

    Mar

  • 16

    May

  • 03

    Jun

GDOT Green Dot
$59.60

0.7 (1.19%)

01/03/19
BTIG
01/03/19
UPGRADE
Target $94
BTIG
Buy
Green Dot upgraded to Buy from Neutral at BTIG
BTIG analyst Mark Palmer upgraded Green Dot (GDOT) to Buy from Neutral with a price target of $94, saying the recent 20% decline in its stock price from the early November highs has created an "attractive entry point for an evolving fintech story." The analyst notes that the company looks to have "sustainable momentum" after beating on consensus earnings and revenue for the past 12 quarters, also highlighting Green Dot's consistent progress in "repositioning its core prepaid debit card business". Palmer adds that he is positive on the company's "expanding roster of enterprise-level programs", and that its Banking as a Service partnerships now include Apple Pay Cash Card (AAPL), Intuit's (INTU) TurboTax prepaid card, Uber's Instant Pay and PayPal's (PYPL) cash in and cash out money services.
03/14/19
RHCO
03/14/19
NO CHANGE
Target $90
RHCO
Buy
Green Dot price target lowered to $90 from $100 at SunTrust
SunTrust analyst Andrew Jeffrey lowers his price target on Green Dot (GDOT) to $90 to reflect the rising "equity risk premium" but also keeps his Buy rating and recommends that investors "add aggressively" into the stock price weakness. The analyst contends that the market is "overstating risk around the MoneyCard renewal at Walmart (WMT)", noting that as Green Dot's most important customer, the risk of losing this business is at near-zero. Jeffrey is also not concerned about the potential for higher BaaS competition given the large total addressable market , stating that Green Dot still retains its "first-mover advantage, vertical integration and reference customers" benefits.
03/07/19
LOOP
03/07/19
NO CHANGE
Target $100
LOOP
Buy
Green Dot offering 'real buying opportunity', says Loop Capital
Loop Capital analyst Joseph Vafi kept his Buy rating and $100 price target on Green Dot, saying the "material price decline" of the stock since reporting Q4 results in unwarranted. The analyst sees the company's tax business, which is "off to a slow start" this year, as a "cash cow" rather than a "growth driver". Vafi further notes that if investors' concern about the "tough P&L comps" after material acceleration in earnings last year is the "worst thing going on", than the stock may be offering a "real buying opportunity for the first time in a year."
02/21/19
LOOP
02/21/19
NO CHANGE
Target $100
LOOP
Buy
Green Dot Q4 margin expansion 'impressive', says Loop Capital
Loop Capital analyst Joseph Vafi kept his Buy rating and $100 price target on Green Dot after its Q4 results, saying the company showed another "impressive margin expansion" in the quarter and its business momentum remains strong. The analyst contends that Green Dot is a true "fin tech" company that is growing its BAAS segment and sees that business driving "material" total addressable market expansion. Vafi also believes that Green Dot's FY19 guidance could prove conservative given the strong macro backdrop, rising e-commerce, and growing direct deposit activity.
AAPL Apple
$187.07

-4.04 (-2.11%)

03/21/19
RHCO
03/21/19
NO CHANGE
RHCO
Apple event may be negative for Netflix, positive for Lions Gate, says SunTrust
SunTrust analyst Matthew Thornton previews Apple's (AAPL) media event scheduled for March 25th, saying the company is likely to unveil a Video Service. The analyst believes that an Apple OTT service could be a positive for Lions Gate (LGF.B) given the participation of the Starz networks but negative for Netflix (NFLX) "if Apple can offer compelling content bundles at compelling prices with a compelling UI and ubiquitous access". Thornton adds that Apple's bundling of its Music with video subscriptions and news subscriptions may be a negative for Spotify (SPOT) and a "modest incremental negative" for Roku (ROKU) if Apple's service app is not on its service.
03/22/19
JPMS
03/22/19
UPGRADE
Target $65
JPMS
Overweight
JPMorgan upgrades Lumentum to Overweight on iPhone volume stabilization
JPMorgan analyst Samik Chatterjee upgraded Lumentum Holdings (LITE) to Overweight from Neutral and raised his price target for the shares to $65 from $50. The stock closed yesterday up $2.44, of 5%, to $52.10. The analyst sees a "solid" outlook for the company's telecom business amid "strong" growth led by 5G investments and upside to synergy targets relative to recent acquisition of Oclaro. Further, he sees limited downside risk relative to volume expectations for Apple's (AAPL) iPhone, which he notes has been a "key driver of sentiment on the shares." Stabilization of its iPhone volume outlook should drive focus back to the "strong" fundamentals in Lumentum's primary telecom business, Chatterjee tells investors in a research note.
03/22/19
MSCO
03/22/19
NO CHANGE
MSCO
Overweight
Apple streaming service timing, robustness key details, says Morgan Stanley
Morgan Stanley analyst Katy Huberty said she expects next Monday's special event from Apple to be focused on new Services launches, specifically a streaming video on demand service and likely a paid subscription news and magazine service. Huberty believes that besides the launch of an Apple Media bundle, which she would view as the most bullish potential announcement, the inclusion of video content from other programmers would be a positive and the launch timing and robustness of the offerings are the most important details to watch. A meaningful delay in the launch of original video content could hamper customer adoption and pricing at or above market for a stand-alone streaming video service could also slow adoption, said Huberty, who has an Overweight rating on Apple shares.
03/25/19
BTIG
03/25/19
NO CHANGE
Target $220
BTIG
Buy
Apple price target raised to $220 from $189 at BTIG
BTIG analyst Walter Piecyk raised his price target on Apple to $220 and kept his Buy rating ahead of its product event today, saying that while the rally of the stock price could stall, his new target assumes the company will return to growth in 2020. The analyst notes that while the recent data points have not been positive for Apple's iPhone business expectations, he continues to expect abating lengthening of the product cycle to materialize in 2020. Piecyk adds that stock buybacks and the company's capital program should be the primary driver Apple's earnings growth.
WMT Walmart
$98.34

0.06 (0.06%)

03/21/19
LOOP
03/21/19
NO CHANGE
Target $102
LOOP
Hold
Walmart grocery sales productivity outperforming supermarkets, says Loop Capital
Loop Capital analyst Andrew Wolf kept his Hold rating and $102 price target on Walmart (WMT), saying the company's U.S. grocery comps outperformed the supermarket chains in 2018 as it has since 2016, even though the gap has narrowed. The analyst notes that Kroger (KR) made the biggest strides last year, and that the company was also the best performer in the 2013-2015 period supermarkets last made strong market share gains. Looking ahead, Wolf says the accelerating food-price inflation anticipated by the USDA could also "bode well for continued further same-store sales acceleration for both Walmart and the grocers in 2019."
03/22/19
UBSW
03/22/19
NO CHANGE
Target $280
UBSW
Buy
Costco price target raised to $280 from $270 at UBS
UBS analyst Michael Lasser raised his price target on Costco (COST) to $280 and kept his Buy rating as part of his deep dive analysis into warehouse clubs. The analyst says the model "remains relevant" and has a "sturdy place" in the omnichannel world, noting that his survey of 1.5K shoppers shows that consumers are loyal to the concept. Lasser cites 91% of Costco members responding that they are "very or somewhat likely to renew", which outpaces intentions recorded at Sam's Club (WMT) and BJ's (BJ). The analyst further notes that Costco has produced 8 consecutive quarters of mid-single-digit core comp growth, suggesting the company's "leadership in this category".
03/20/19
EVER
03/20/19
INITIATION
Target $95
EVER
In Line
Walmart initiated with an In Line at Evercore ISI
Evercore ISI analyst Greg Melich initiated Walmart with an In Line rating and $95 base case price target. He thinks its steady cash flow generation, premium dividend, and "fortress balance sheet" have value in the current environment, but he believe that its safe haven status is largely understood and reflected in its current valuation.

TODAY'S FREE FLY STORIES

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

06:55
12/08/19
12/08
06:55
12/08/19
06:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:31
12/07/19
12/07
19:31
12/07/19
19:31
Hot Stocks
Magenta reports results from MGTA-145 stem cell mobilization program »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PFE

Pfizer

$38.29

0.26 (0.68%)

, BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:29
12/07/19
12/07
19:29
12/07/19
19:29
Hot Stocks
Bristol-Myers Squibb-Pfizer Alliance reports analysis of Eliquis »

The Bristol-Myers…

PFE

Pfizer

$38.29

0.26 (0.68%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

UMRX

Unum Therapeutics

$0.70

0.0177 (2.61%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Hot Stocks
Unum Therapeutics announces Phase 1 clinical updates for T-cell therapies »

Unum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

19:23
12/07/19
12/07
19:23
12/07/19
19:23
Hot Stocks
Autolus presents new data on T cell therapies in leukemia, lymphoma »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:19
12/07/19
12/07
19:19
12/07/19
19:19
Hot Stocks
Bristol-Myers says lisocabtagene maraleucel study met both endpoints »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

SGEN

Seattle Genetics

$117.52

0.37 (0.32%)

19:16
12/07/19
12/07
19:16
12/07/19
19:16
Hot Stocks
Seattle Genetics reports updated Adcetris plus Opdivo Hodgkin lymphoma data »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 15

    Mar

GILD

Gilead

$67.09

1.16 (1.76%)

19:12
12/07/19
12/07
19:12
12/07/19
19:12
Hot Stocks
Gilead's Kite announces long-term data from ZUMA-1 study in lymphoma »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CRTX

Cortexyme

$28.00

-6.15 (-18.01%)

19:10
12/07/19
12/07
19:10
12/07/19
19:10
Hot Stocks
Cortexyme says COR388 reduced levels of ApoE protein in Phase I study »

Cortexyme announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$3.40

0.015 (0.44%)

12:15
12/07/19
12/07
12:15
12/07/19
12:15
Hot Stocks
Mallinckrodt presents data on infantile spasms predictive model »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

12:13
12/07/19
12/07
12:13
12/07/19
12:13
Hot Stocks
Stoke Therapeutics presents preclinical data from studies of STK-001 »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTO

Aptose Biosciences

$2.55

-0.04 (-1.54%)

12:11
12/07/19
12/07
12:11
12/07/19
12:11
Hot Stocks
Aptose reports CG-806 data in patients with chronic lymphocytic leukemia »

Aptose Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$18.22

2.9 (18.93%)

10:09
12/07/19
12/07
10:09
12/07/19
10:09
Hot Stocks
Epizyme announces 'positive, mature data' for Phase 2 trial of tazemetostat »

Epizyme reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

10:07
12/07/19
12/07
10:07
12/07/19
10:07
Hot Stocks
Principia Biopharma announces 'consistent positive data' for PRN1008 »

Principia Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$200.99

1.64 (0.82%)

, GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

09:31
12/07/19
12/07
09:31
12/07/19
09:31
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$200.99

1.64 (0.82%)

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

GOOG

Alphabet

$1,341.23

12.23 (0.92%)

AAPL

Apple

$270.71

5.15 (1.94%)

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

SQ

Square

$68.00

0.85 (1.27%)

TWTR

Twitter

$30.19

0.16 (0.53%)

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

FSLR

First Solar

$53.36

1.06 (2.03%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.23

0.15 (2.12%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

AKS

AK Steel

$3.24

0.065 (2.05%)

MT

ArcelorMittal

$17.88

0.43 (2.46%)

NUE

Nucor

$57.60

1.13 (2.00%)

STLD

Steel Dynamics

$35.10

0.67 (1.95%)

TMST

TimkenSteel

$6.90

0.41 (6.32%)

X

U.S. Steel

$13.95

0.615 (4.61%)

AA

Alcoa

$20.60

0.68 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 06

    Feb

  • 26

    Feb

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

09:27
12/07/19
12/07
09:27
12/07/19
09:27
Hot Stocks
Fate Therapeutics reports initial clinical data for FT516 and FT50 »

Fate Therapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

09:25
12/07/19
12/07
09:25
12/07/19
09:25
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

CRVS

Corvus Pharmaceuticals

$4.26

-0.36 (-7.79%)

09:23
12/07/19
12/07
09:23
12/07/19
09:23
Hot Stocks
Corvus reports initial results from Phase 1/1b trial of CPI-818 »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:21
12/07/19
12/07
09:21
12/07/19
09:21
Hot Stocks
Karyopharm announces updated Xpovio data in multiple myeloma »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

09:18
12/07/19
12/07
09:18
12/07/19
09:18
Hot Stocks
AbbVie reports results of 7.5-year pooled analysis of Imbruvica »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

09:16
12/07/19
12/07
09:16
12/07/19
09:16
Hot Stocks
Sierra Oncology reports new analyses of momelotinib compared to ruxolitinib »

Sierra Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.